Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release

  • Tell a FriendPrint

Panic disorder(PD)is a disabling psychiatric condition associated with significant impairment in psychosocial, occupational functioning and quality of life, as mentioned by mogotsi et al. So, most patients with panic disorder suffers from the consequences of the impairment in occupational function. This impairment is not only individual problem, but also social one. Since productivity is very...

Brief Summary

Panic disorder(PD)is a disabling psychiatric condition associated with significant impairment in psychosocial, occupational functioning and quality of life, as mentioned by mogotsi et al. So, most patients with panic disorder suffers from the consequences of the impairment in occupational function. This impairment is not only individual problem, but also social one. Since productivity is very important item required to employees, lost productive time among workers with psychiatric illness should be reduced by the proper management. But few data were reported in this field by now.

  • Study Type: Interventional
  • Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research

Intervention(s) in this Clinical Trial

  • Drug: Paroxetine CR

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • 1. Male or female outpatients aged 20-50 years
  • 2. In female, is eligible to enter this study if she is if
  • Non-childbearing potential(note:women who are 6 months post-menopausal are not considered women of child-bearing potential)
  • child-bearing potential, has a negative urine dipstick pregnancy test, and is practicing a clinically acceptable method of contraception such as oral contraception, surgical sterilization, I.U.D.,systemic contraception, or double barrier contraception(any two of diaphragm/spermicidal foar/condom)
  • 3. Subject currently meets the diagnosis for PD according to korean version of Anxiety Disorder Interview Schedule for DSM-IV(ADIS-IV) through a comprehensive psychiatric evaluation and not being treated currently.
  • 4. Subject must have the ability to comprehend the key components of the consent form and provide informed consent.

Exclusion Criteria:

  • 1. Subject who has a history of any other major medical or psychiatric illnesses except
  • PD or PD with major depressive disorder.
  • 2. Subject who retired or left his job or who plan to retire within two years.
  • 3. is a current homicidal or suicidal risk in the investigator's judgement.
  • 4. is currently pregnant, lactating or planning to become pregnant within the next 3 months
  • 5. is currently participating in any other clinical trial or taking any non-approved or experimental medication.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 20 Years

Maximum Age for this Clinical Trial: 50 Years

Clinical Trial Investigator Information

Lead Investigator: Inje University Other

Overall Clinical Trial Officials and Contacts

Jong-Min Woo, Master Principal Investigator Seoul Paik Hospital, Inje University  

Overall Contact: Eun-Joo Jung +82-2-2270-0940 menfipro@naver.com

Additional Information

Information obtained from ClinicalTrials.gov on February 09, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00492414

Study ID Number: COL110010

ClinicalTrials.gov Identifier: NCT00492414

Health Authority: South Korea: Korea Food and Drug Administration (KFDA)

  • Tell a FriendPrint

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00492414